Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Lemairamin and Pramiracetam — mechanism, side effects, legal status, and pricing.
Lemairamin is a non-peptide small-molecule cinnamamide alkaloid (N-phenethyl cinnamide) natural product, not approved for human use in any jurisdiction. All available data are preclinical (rodent, zebrafish, C. elegans, in vitro, and computational). It is sold exclusively as an unregulated 'research chemical' explicitly labeled 'not for human consumption'; quality, purity, and identity are not independently verified by any regulatory body. No human clinical trials, pharmacokinetic studies, or safety data exist.
Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.
Lemairamin
Pramiracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Lemairamin
No pricing data yet.
Check Lemairamin prices →Pramiracetam
No pricing data yet.
Check Pramiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Lemairamin
2
COAs
99.8%
Avg purity
2
Labs
Pramiracetam
2
COAs
99.9%
Avg purity
2
Labs
No human data exist. No completed or registered human clinical trials were located on ClinicalTrials.gov, and no PubMed-indexed human pharmacokinetic, safety, or efficacy studies exist. All available data are preclinical: In transgenic Alzheimer's mice, gx-50 disassembled Aβ oligomers, decreased cortical Aβ accumulation, inhibited Aβ-induced neuronal apoptosis and calcium toxicity, improved Morris water maze performance, and was reported to cross the blood-brain barrier (Tang et al. 2013). In mouse and rat pain models (formalin tonic, neuropathic, bone-cancer pain), subcutaneous and intrathecal lemairamin dose-dependently reduced pain hypersensitivity/mechanical allodynia without evident tolerance, linked to spinal α7 nAChR activation and downstream IL-10/β-endorphin release (Wang et al. 2020). Murine microglial cell cultures showed gx-50 activation of α7 nAChR engaged JAK2/STAT3 and PI3K/AKT signaling to suppress pro-inflammatory cytokine secretion (Shi et al. 2016). Zebrafish DSS-induced colitis models showed lemairamin attenuated intestinal inflammation via Akt signaling (2024). C. elegans studies reported WGX-50 promoted markers of healthy ageing (daf-16/skn-1 longevity genes, 2025).
Key references
Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.
Lemairamin and Pramiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs